Two Cases of SMARCA4-Deficient Non-small Cell Lung Cancer (NSCLC) with Improved Performance Status (PS) after Treatment with Immune Checkpoint Inhibitors (ICIs)

Akiko Koizumi; Yukiho Tamura; Ryohei Yoshida; Chie Mori; Yusuke Ono; Mishie Tanino; Yusuke Mizukami; Takaaki Sasaki

doi:10.7759/cureus.37656

Two Cases of SMARCA4-Deficient Non-small Cell Lung Cancer (NSCLC) with Improved Performance Status (PS) after Treatment with Immune Checkpoint Inhibitors (ICIs)

Cureus. 2023 Apr 16;15(4):e37656. doi: 10.7759/cureus.37656. eCollection 2023 Apr.

Authors

Akiko Koizumi¹, Yukiho Tamura¹, Ryohei Yoshida², Chie Mori², Yusuke Ono³, Mishie Tanino⁴, Yusuke Mizukami⁵, Takaaki Sasaki²

Affiliations

¹ Medicine, Asahikawa Medical University School of Medicine, Asahikawa, JPN.
² Respiratory Center, Asahikawa Medical University Hospital, Asahikawa, JPN.
³ Biomedical Research, Sapporo Higashi Tokushukai Hospital, Sapporo, JPN.
⁴ Diagnostic Pathology, Asahikawa Medical University Hospital, Asahikawa, JPN.
⁵ Gastroenterology and Hematology/Oncology, Department of Medicine, Asahikawa Medical University, Asahikawa, Hokkaido, JPN.

Abstract

SWItch/Sucrose Non-Fermentable (SWI/SNF)-related, matrix-associated, actin-dependent regulator of chromatin, subfamily A, member 4 (SMARCA4) mutations are commonly reported in non-small cell lung cancer (NSCLC) and are associated with a poor prognosis. There is insufficient evidence regarding the efficacy of immune checkpoint inhibitors (ICIs) in SMARCA4-deficient NSCLC patients with poor performance status (PS). We report two cases of advanced SMARCA4-deficient NSCLC treated with ICIs, in which marked regression of the tumor and improved general condition of the patients were achieved.

Keywords: brg1; immune checkpoint inhibitor; non-small cell lung cancer; performance status; smarca4-deficient.

Publication types

Case Reports